Dawnrays Pharmaceutical (Holdings) Limited
HKSE 2348.HK
Dawnrays Pharmaceutical (Holdings) Limited EBIT for the year ending December 31, 2023: USD 58.46 M
-
Dawnrays Pharmaceutical (Holdings) Limited EBIT for the year ending December 31, 2022 was USD 63.58 M, a 7.35% change year over year.
-
Dawnrays Pharmaceutical (Holdings) Limited EBIT for the year ending December 31, 2021 was USD 59.23 M, a 15.02% change year over year.
-
Dawnrays Pharmaceutical (Holdings) Limited EBIT for the year ending December 31, 2020 was USD 51.49 M, a 24.45% change year over year.
-
Dawnrays Pharmaceutical (Holdings) Limited EBIT for the year ending December 31, 2019 was USD 41.38 M, a -24.90% change year over year.
| Date | EBIT | EBITDA | Net Income | EPS (Diluted) |
|---|
Don’t Miss A Beat
| CEO | Ms. Liwei Yu |
| IPO Date | July 11, 2003 |
| Location | Hong Kong |
| Headquarters | CNT Tower |
| Employees | 1,175 |
| Sector | Healthcare |
| Industries | |
Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, and oral antibiotics. It also provides and system specific medicines comprising cardiovascular systems; anti-allergic, anti-HBV, and digestive systems; urinary systems; and anti-pyretic analgesic, respiratory, and endocrine system drugs in the form of tablets, capsules, and granules. The company was founded in 1995 and is headquartered in Wan Chai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited is a subsidiary of Fortune United Group Limited.
Past 5 years
USD 0.56
USD 1.06
StockViz Staff
February 3, 2025
Any question? Send us an email